Industry News

The facility in Suzhou, China, which also passed an EU audit in 2024, will support commercial production of the dengue vaccine for Brazil.

The partnership links early formulation and clinical supply with late-stage scale-up and commercial manufacturing.

The digital collaboration links clinical trial, registry, and medical record data to support study design and faster evidence generation.

The partnership links academic research with an integrated discovery platform to move programs toward clinical development.

The five-year plan includes local production and clinical R&D collaboration designed to strengthen pandemic preparedness in the country.

The $46 million investment targets U.S. manufacturing capacity for ropeginterferon alfa-2b used to treat polycythemia vera in adults.

The collaboration aims to onshore active pharmaceutical ingredient and finished dose production for the essential medicine used in hospitals nationwide.

The alliance looks to achieve shorter vein-to-vein timelines for cell and gene therapy and lower production costs.

The pharmaceutical company’s new lipid-based microbubble technology targets upstream cell selection and activation steps.

The collaboration with the National Research Council of Canada and Daresbury Proteins aims to target higher-yield expression systems to streamline conjugate production.

The CDMO will provide access to up to 50 million vaccine doses during a future pandemic.

The agreement covers a preclinical trispecific candidate for B-cell mediated autoimmune diseases.

Manufacturing is expected to begin in 2026 at OXB’s sites in Oxford, UK, and Durham, North Carolina.

The transaction provides infrastructure to broaden Nanologica’s product portfolio beyond silica-based purification media, according to the announcement.

The CDMO completed development, scale-up, and commercialization of the delivery system across two sites within five months.

The authorization for the U.S.-headquartered CDMO allows biologics and biosimilars made at the site to be commercialized in the South American country.

The collaboration expands automated cell therapy manufacturing beyond T cells into hematopoietic stem cells.

Manufacturing of ExpreS2ion Biotechnologies’ Nipah vaccine program is scheduled to begin in the first quarter of 2026 under an EU-funded development program.

The tool is designed to reduce the time and resources required to convert paper batch records into digital workflows, according to the company.

The software is intended to support earlier decision-making in solid-form selection during drug substance development, the company said.

Construction of the Saarland facility is scheduled to begin in 2026, with operations expected to start in 2031.

The collaboration covers preclinical pharmacology studies and clinical supply to support planned IND filings in China and the United States.

The financing will support global deployment of the company’s integrated, GMP-ready manufacturing facilities in Europe, Japan, and the U.S.

The move follows the sale of Noramco’s API assets and positions Halo for expanded sterile manufacturing capacity, according to the company.

The collaboration will evaluate GMP-ready robotic systems for scalable, high-throughput cell therapy production.

The $30 million expansion adds 2,000-liter single-use GMP capacity to support late-stage and commercial biologics programs.

The agreement centers on CMC execution and GMP manufacturing support for multiple clinical-stage fusion protein programs.

Manufactured under cGMP conditions, the additions include low-endotoxin and enzyme-free formulations for laboratories and manufacturing use, the company said.

The investment supports compliant manufacturing of non-bacterial beta-lactam medicines amid stricter cross-contamination controls.

The Grissom Aeroplex expansion in Bunker Hill adds GMP capacity for high-volume therapeutic and diagnostic production.